Elite Pharma receives FDA approval for generic Methotrexate; market $64.3M annual sales

ELITE PHARMACEUTICALS INC /NV/

FDA approved ANDA for generic Methotrexate Sodium 2.5 mg tablets on May 16, 2024.
Product will be marketed under Elite Laboratories, Inc. label.
IQVIA reports $64.3 million in annual U.S. generic market sales (12 months ending Mar 2024).

item 7.01 item 9.01

ELITE PHARMACEUTICALS INC /NV/ filing history →

Source: SEC EDGAR

accession 0001493152-24-020707

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.